Now approved in EU

Defitelio® (defibrotide) 
The European Commission has granted a Marketing Authorization for Defitelio® (defibrotide) for the treatment of severe hepatic veno-occlusive disease (sVOD) in adults and children undergoing hematopoietic stem cell transplantation therapy.

 

Defibrotide is marketed in E.U. as Defitelio® - Learn more

General News

Financial News

Medical Information

For any medical information enquiries please contact:
Email:medical-enquiries@gentium.it
Tel: +39 031 5373 112

In focus

Gentium S.p.A. is a
Jazz Pharmaceuticals company.

To learn more about Jazz Pharmaceuticals, click here

Gentium S.p.A. - P.IVA n. 02098100130